Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.09:18

In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631598195?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-29 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631598195","market":"us","top_or_hot":-1,"title":"Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing","media":"Simply Wall St.","content":"<div>\n<p>In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 09:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0205194284.USD","symbol_name":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph","article_id":"2631598195","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2631598195","pubTimestamp":1777425531,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics license application with the FDA for this one-time in vivo CRISPR treatment.\nThe HAELO trial showed lonvo-z cut hereditary angioedema attacks very sharply versus placebo, supporting Intellia’s push to bring what could become the first in vivo CRISPR-based gene editing therapy to market.\nNext,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","NTLA":"Intellia Therapeutics Inc","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4198":"医疗保健用品","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","HAE":"美国血液技术","BK4139":"生物科技","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4535":"淡马锡持仓","LABU":"三倍做多标普生物-Direxion","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4588":"碎股","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC"},"translate_title":"为什么Intellia Therapeutics(NTLA)在3期HAE基因编辑结果和FDA备案后股价下跌13.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1.5,"HAE":1.5,"LABU":1.5},"content_text":"In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics license application with the FDA for this one-time in vivo CRISPR treatment. The HAELO trial showed lonvo-z cut hereditary angioedema attacks very sharply versus placebo, supporting Intellia’s push to bring what could become the first in vivo CRISPR-based gene editing therapy to market. Next, we’ll examine how these Phase 3 results and the FDA filing for lonvo-z may reshape Intellia’s investment narrative. AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementIntellia Therapeutics Investment Narrative RecapTo own Intellia, you need to believe one time in vivo CRISPR treatments can become viable products and support a broader gene editing platform. The Phase 3 HAELO success and rolling FDA filing make lonvo z the key near term catalyst, while regulatory and commercial execution risks across a very small set of lead programs remain the biggest threat to the story. Alongside the HAELO readout, Intellia moved to raise about US$150 million in a follow on equity offering. For investors, that ties directly into the catalyst path for lonvo z and nex z, because funding decisions help determine how far Intellia can advance late stage trials and pre launch work before any potential product revenue arrives. Yet even with strong trial data, investors should also be aware of the risk that payer pushback on high upfront gene editing costs could... Read the full narrative on Intellia Therapeutics (it's free!)Intellia Therapeutics' narrative projects $593.8 million revenue and $76.0 million earnings by 2029.Uncover how Intellia Therapeutics' forecasts yield a $25.29 fair value, a 92% upside to its current price.Exploring Other PerspectivesNTLA 1-Year Stock Price Chart Before this data, the most optimistic analysts were already modeling revenue near US$6.0 billion and about US$1.9 billion in earnings by 2029, which is far more bullish than consensus and could look different once the lonvo z news is fully reflected.Explore 5 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.Want Some Alternatives?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Uncover the next big thing with 24 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631598195","isCrawlerRequest":true}